Woebot Health enrolls the first patient in a pivotal clinical trial of WB001 for postpartum depression

San Francisco–() –Woebot health Today I announce the enrollment of the first patient in a pivotal clinical trial to evaluate safety and efficacy WB001an investigative digital treatment for postpartum depression (PPD) that was awarded Penetrating device design by the U.S. Food and Drug Administration (FDA) in 2021. This multicenter, randomized, double-blind, actively controlled study is recruiting women ages 22-45 who had given birth in the past 3 months and had mild-to-moderate postpartum depression.

Despite the high prevalence of postpartum postpartum mood disorder, women’s healthcare needs remain chronically underserved. Too many women suffer in silence, said Athena Robinson, PhD, chief medical officer at Woebot Health, who seek support often struggle to access the resources they need. “With WB001, our focus is to enable early interventions by making mental health care more accessible to mothers in their time of need.”

WB001 combines a therapeutic alliance with human-centered design, machine learning techniques, and well-established principles from cognitive-behavioral therapy and interpersonal therapy (IPT) to treat postpartum depression. It is based on Woebot, a relational agent that enables routing by repeating some elements of human relations. To date, WB001 will be the first digital therapy of its kind to be authorized by the Food and Drug Administration.

said Robbert Zusterzeel, MD, Ph.D. MPH, Vice President, Organizational Science and Strategy, Woebot Health. “The real-world evidence generated from this study will provide us with data to understand the effect of WB001 adjunctively on women’s usual treatment, including pharmacotherapy and psychotherapy. We look forward to sharing our progress as we continue to evaluate its effectiveness.”

About the Pivotal Clinical Trial of Postpartum Depression: A Randomized Clinical Trial of WB001

The purpose of the study was to determine whether, for women with postpartum depression, WB001 as an adjunct to usual treatment (TAU) could reduce depressive symptoms compared to an educational control with adjuvant TAU ​​at the end of 8 weeks of treatment, as measured by the HAM-D6 scale. Clinically validated, which assesses symptoms of depression such as depressed mood, guilt, work and activities, psychomotor retardation, psychological anxiety, and general physical symptoms.

WB001 therapy consists of PPD-specific psychoeducational lessons and CBT-specific skills or tools used in a real, out-of-clinic setting. Lessons teach information specific to postpartum depression to normalize and contextualize postpartum experiences, as well as provide information on effective mood management and mental health promotion in the context of the newly given birth.

More information about the trial and reflections on its potential industry-wide impact on this Maternal Health Awareness Day These are explored on Woebot Health’s website Articles.

About Woebot Health

Woebot Health is the mental health ally of individuals and companies that puts personal growth in people’s hands, wherever they are. Our suite of digital therapies and behavioral health products combine natural language processing, decades of clinically proven technologies, and a relational agent called Woebot, which together form the foundation for mental health solutions that engage at scale and fit people’s lives.

For more information visit woebothealth.com Or follow Woebot on FacebookAnd Twitter And linkedin.

Leave a Reply

Your email address will not be published. Required fields are marked *